Medable and Redox partner to offer the first

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
41
Medable and Redox partner to offer the first fully-integrated medical research platform

PALO ALTO, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Medable, the leading application and analytics platform for healthcare, and Redox, the leader in cloud-based healthcare API services, today announced the formation of a strategic technology partnership to enable the use of EHR data to streamline mobile medical research.

The partnership will enable the first fully-integrated medical research platform between smart phones and EHRs. By using Medable’s platform and Redox’s API services, clinical trial leaders and health researchers can integrate patient-generated health data into the electronic health record. Redox and Medable cloud-based technologies are in use independently at more than 100 health systems across the United States.  With the partnership, the two companies are identifying overlapping and potential customers and deploying their technologies to enable fully-integrated mobile clinical trial and clinical research applications.

Medable’s Axon enables any clinical researcher to build a fully HIPAA-compliant mobile application for study participation, without a developer. A process that used to take over six months can now be completed in a few hours, resulting in a mobile application that is proven to increase research participation and expand the scope of data collected.  An application built using Axon enables mobile consent and patient reported data collection directly from participants and enables additional data such as connected devices and activity and contextual data captured by the participant’s smart phone.

While Medable has seen rapid adoption by healthcare enterprises and researchers alike, EHR integration is an important advancement. By integrating data in the EHR, there is a unified source of record for a patient.  Retrieving the data from the medical record enables Medable analytics capabilities to derive insights from the full suite of patient data collected within and outside of the walls of the hospital.

“Healthcare researchers want to leverage mobile to provide connected care and continuous data collection,” said Michelle Longmire, MD, Medable’s CEO.  “It is important to maintain a source of record for every patient, and for patient generated data to really play a role in healthcare. We are excited to work with Redox to close the loop between mobile and the EMR both for the opportunity to provide better care and new insights from data.”

Redox provides a platform that facilitates the secure transfer of data between healthcare organization’s electronic health record systems and cloud-based technology providers. The company specializes in enabling modern technologies, like Medable, to easily integrate with legacy healthcare IT systems with a modern API.

“Medable’s platform and mobile first approach provides a clear path to accelerating the discovery of medical breakthroughs,” said Luke Bonney, CEO, Redox. “We couldn’t be more excited to empower innovation like Medable’s. Our integration services will allow Medable to access critical data elements that will support its work and improve the user experience for researchers.”

ABOUT MEDABLE

Privately-held Palo Alto, California-based Medable provides a comprehensive, secure HIPAA-compliant cloud-based platform that has been created specifically for the needs in healthcare.  Medable’s Cortex is the fastest path to scalable, interoperable, HIPAA compliant applications. Medable’s Axon delivers “no coding required” smartphone clinical studies on a secure, compliant technology stack. Medable’s Cerebrum is the first cloud-based machine learning solution created specifically for healthcare apps. For more information visit: www.medable.com

ABOUT REDOX

Redox is the modern API for healthcare, allowing best-in-class software to easily and securely interoperate with EHRs in a health system infrastructure. Through Redox's standardized data models and interoperable network, software applications connect to Redox once and then have the ability to integrate with any health system and EHR. With hundreds of applications integrated, Redox is the leading healthcare interoperability platform with the largest ecosystem of enterprise applications. Redox is headquartered in Madison, Wisconsin: the land of beer, cheese, and health tech. Learn more and join the network at www.redoxengine.com .

Gary Poole, PR Director

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading